论文部分内容阅读
目的:探讨RhoC在葡萄胎、侵袭性葡萄胎、绒癌中的表达及与葡萄胎恶变的相关性。方法:应用免疫组化的方法检测25例未恶变的葡萄胎、15例恶变倾向的葡萄胎、10例侵袭性葡萄胎及15例绒癌组织中RhoC的表达情况,采用化学发光法测定了40例葡萄胎患者288次血人绒毛膜促性腺激素(HCG),并结合临床资料进行分析。结果:RhoC在侵袭性葡萄胎及绒癌中表达明显高于葡萄胎(P<0.01);恶变倾向的葡萄胎中RhoC表达也明显高于未恶变的葡萄胎(P<0.01)。葡萄胎恶变与RhoC的表达、血HCG值及卵巢黄素化囊肿呈正相关(P<0.01、P<0.01、P<0.05)。9例血HCG持续阳性和6例血HCG降而复升的葡萄胎患者发生恶变,且9例血HCG持续阳性的患者葡萄胎中RhoC表达显著高于其他患者。结论:RhoC可能与滋养细胞的侵袭过程及程度有关,RhoC的表达上调可能是滋养细胞恶性转化的早期事件,检测葡萄胎组织中RhoC的蛋白表达,可能成为预测葡萄胎恶变的新指标,为临床预防性化疗提供依据。
Objective: To investigate the expression of RhoC in hydatidiform mole, invasive hydatidiform mole and choriocarcinoma and its correlation with hydatidiform mole malignant transformation. Methods: Immunohistochemical method was used to detect the expression of RhoC in 25 cases of nonmalignant hydatidiform mole, 15 cases of malignant transitional mole, 10 cases of invasive mole and 15 cases of choriocarcinoma. The chemiluminescence method was used to determine the expression of RhoC Cases of hydatidiform blood of 288 blood human chorionic gonadotropin (HCG), combined with clinical data analysis. Results: The expression of RhoC in invasive hydatidiform mole and choriocarcinoma was significantly higher than that in hydatidiform mole (P <0.01). The expression of RhoC was also significantly higher in malignant metaplasia than in nonmalignant hydatidiform mole (P <0.01). The malignant transformation of hydatidiform mole was positively correlated with the expression of RhoC, blood HCG and luteinized cyst of ovary (P <0.01, P <0.01, P <0.05). Nine patients with persistent positive HCG and 6 patients with hydatidiform moles with ascending and descending hydatidiform mole developed malignant transformation. The expression of RhoC in nine patients with persistent positive HCG was significantly higher than that in other patients. Conclusion: RhoC may be related to the invasion process and degree of trophoblast cells. Up-regulation of RhoC may be an early event of trophoblastic malignant transformation. Detecting RhoC protein expression in hydatidiform mole may be a new indicator to predict malignant transformation of hydatidiform mole. Prophylactic chemotherapy to provide the basis.